In further studies we have clearly shown that by combining a Shh inhibitor (vismodegib or ITRA) and a COX inhibitor (the NSAID Sulindac) it is possible to obtain superior anti-tumor efficacy as compared to either class alone in treating BCCs in our murine model of NBCCS (Figure 11). The gene discussed is SHH; the disease is nevoid basal cell carcinoma syndrome.